LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lineage Cell Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.95−0.03 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $249.13M
- P/E (TTM)
- –
- Dividend yield
- –
Lineage Cell Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenues [Member] | $12.33M | $13.91M | $13.61M | $9.82M | $9.67M | $8.23M | $8.15M | $7.31M | $4.88M | $6.65M | $7.59M | – | 94.2% | +27.5% |
| Upfront License Fees [Member] | $4.10M | $6.04M | $6.45M | $8.04M | $9.67M | $8.23M | $8.15M | $7.31M | $4.88M | $6.65M | $7.59M | $7.71M | 31.4% | -57.6% |
| Royalties, License and Other Revenues [Member] | $758.00K | $865.00K | $947.00K | $992.00K | $1.25M | $1.33M | $1.35M | $1.41M | $1.31M | $1.35M | $1.36M | – | 5.8% | -39.3% |
By region
From the segment and revenue-disaggregation notes of Lineage Cell Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.